What this is
- How it works
- How it works isn't classified yet
- How it’s given
- “A cocktail of lytic Shigella-specific bacteriophages orally administered with sodium bicarbonate solution”In the company’s words, NCT05182749 on ClinicalTrials.gov
- Tested for
- Shigellosis
- Main trialPhase 1/2
- “The study is a first-in-human Phase 1/2a randomized, double-blind, placebo-controlled trial to assess the clinical safety and efficacy of ShigActive in healthy adults with experimental Shigella challenge.”In the company’s words, NCT05182749 on ClinicalTrials.gov
- Other names
- ShigActive
Other drugs for Shigellosis
- S. Flexneri-S. Sonnei bivalent conjugate vaccineBeijing Zhifei Lvzhu Biopharmaceutical Co., Ltd · Phase 3
- ShigETEC liveEveliqure Biotechnologies GmbH · Phase 2
- IVT Shigella-04Inventprise Inc. · Phase 1
Coming up0
No dates coming up.
Changes0
Last 90 daysNo changes yet. We started recording changes on 6 Nov 2026.
Trials1
| Trial | Phase | Completes | What it tests |
|---|---|---|---|
| Phase 1/2Active, not recruiting | 9 Dec 2024 | Safety and Efficacy of the Bacteriophage Preparation, ShigActive™, in a Human Experimental Model of Shigellosis |
A trial in both registries shows both numbers.
About
- Sources
- ClinicalTrials.gov updated 19 Nov 2026 · EU trials register (CTIS) updated 19 Nov 2026 · openFDA updated 19 Nov 2026